BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32589738)

  • 1. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
    El-Maouche D; Merke DP; Vogiatzi MG; Chang AY; Turcu AF; Joyal EG; Lin VH; Weintraub L; Plaunt MR; Mohideen P; Auchus RJ
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2771-8. PubMed ID: 32589738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
    Sarafoglou K; Barnes CN; Huang M; Imel EA; Madu IJ; Merke DP; Moriarty D; Nakhle S; Newfield RS; Vogiatzi MG; Auchus RJ
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4666-e4679. PubMed ID: 34146101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
    Ng SM; Stepien KM; Krishan A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012517. PubMed ID: 32190901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
    Auchus RJ; Sarafoglou K; Fechner PY; Vogiatzi MG; Imel EA; Davis SM; Giri N; Sturgeon J; Roberts E; Chan JL; Farber RH
    J Clin Endocrinol Metab; 2022 Feb; 107(3):801-812. PubMed ID: 34653252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.
    Nella AA; Mallappa A; Perritt AF; Gounden V; Kumar P; Sinaii N; Daley LA; Ling A; Liu CY; Soldin SJ; Merke DP
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4690-4698. PubMed ID: 27680873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid 17-Hydroxyprogesterone in Hair Is a Potential Long-Term Biomarker of Androgen Control in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
    Auer MK; Krumbholz A; Bidlingmaier M; Thieme D; Reisch N
    Neuroendocrinology; 2020; 110(11-12):938-949. PubMed ID: 31711056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse circadian glucocorticoid treatment in prepubertal children with congenital adrenal hyperplasia.
    Dubinski I; Bechtold Dalla-Pozza S; Bidlingmaier M; Reisch N; Schmidt H
    J Pediatr Endocrinol Metab; 2021 Dec; 34(12):1543-1548. PubMed ID: 34523293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Congenital adrenal hyperplasia due to 21-hydroxylase deficiency--management in adults].
    Ambroziak U; Bednarczuk T; Ginalska-Malinowska M; Małunowicz EM; Grzechocińska B; Kamiński P; Bablok L; Przedlacki J; Bar-Andziak E
    Endokrynol Pol; 2010; 61 Suppl 1():7-21. PubMed ID: 22127631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia].
    Xiao HW; Ma HM; Su Z; Du ML; Li YH; Chen HS; Chen QL
    Zhonghua Er Ke Za Zhi; 2012 Apr; 50(4):301-7. PubMed ID: 22801236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.
    Debono M; Mallappa A; Gounden V; Nella AA; Harrison RF; Crutchfield CA; Backlund PS; Soldin SJ; Ross RJ; Merke DP
    Eur J Endocrinol; 2015 Dec; 173(6):727-37. PubMed ID: 26340969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between androstenedione and 17-hydroxyprogesterone levels in the saliva and plasma of patients with congenital adrenal hyperplasia.
    Juniarto AZ; Goossens K; Setyawati BA; Drop SL; de Jong FH; Faradz SM
    Singapore Med J; 2011 Nov; 52(11):810-3. PubMed ID: 22173250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
    Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
    Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.
    Melin J; Parra-Guillen ZP; Michelet R; Truong T; Huisinga W; Hartung N; Hindmarsh P; Kloft C
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32052005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia.
    Mallappa A; Sinaii N; Kumar P; Whitaker MJ; Daley LA; Digweed D; Eckland DJ; Van Ryzin C; Nieman LK; Arlt W; Ross RJ; Merke DP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1137-45. PubMed ID: 25494662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules.
    Neumann U; Braune K; Whitaker MJ; Wiegand S; Krude H; Porter J; Digweed D; Voet B; Ross RJM; Blankenstein O
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1433-e1440. PubMed ID: 32888021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-Hydroxyprogesterone in children, adolescents and adults.
    Honour JW
    Ann Clin Biochem; 2014 Jul; 51(Pt 4):424-40. PubMed ID: 24711560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scalp hair 17-hydroxyprogesterone and androstenedione as a long-term therapy monitoring tool in congenital adrenal hyperplasia.
    Noppe G; de Rijke YB; Koper JW; van Rossum EF; van den Akker EL
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):522-7. PubMed ID: 27061431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital Adrenal Hyperplasia in Children: A Pilot Study of Steroid Hormones Expressed as Sex- and Age-Related Standard Deviation Scores.
    Clausen CS; Ljubicic ML; Main KM; Andersson AM; Petersen JH; Frederiksen H; Duno M; Johannsen TH; Juul A
    Horm Res Paediatr; 2020; 93(4):226-238. PubMed ID: 33017824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invited Commentary: A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
    Speiser PW
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32777044
    [No Abstract]   [Full Text] [Related]  

  • 20. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
    Verma S; Vanryzin C; Sinaii N; Kim MS; Nieman LK; Ravindran S; Calis KA; Arlt W; Ross RJ; Merke DP
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):441-7. PubMed ID: 19486026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.